Business
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthc
About this update from Humana Inc.
[{"type":"image","alt":"Plus Therapeutics Inc.","displaySize":"","headline":null,"caption":"Plus Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":172,"url":"https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PAd6youIFzv4mViQD8View--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0MQ--/https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c","width":300,"height":172}},"lazy":false},{"type":"text","content":"HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide.","length":564,"tagName":"p"},{"type":"text","content":"The addition of Highmark expands CNSide’s total covered lives from approximately 67 million to 75 million, representing continued progress toward the Company’s 2026 objective of 150 million covered lives, while expanding patient access across the U.S. The agreement is expected to further accelerate adoption of CNSide across oncology centers by reducing reimbursement barriers for ordering physicians.","length":402,"tagName":"p"},{"type":"text","content":"“Securing coverage with Highmark, a leading Blue Cross Blue Shield-affiliated payer, marks another important milestone in expanding patient access to CNSide and reinforces the growing recognition among payers of its clinical and economic value,” said Russ Havranek, EVP Corporate and Commercial Strategy at Plus Therapeutics. “We continue to make progress toward broad national coverage and expanded adoption.”","length":415,"tagName":"p"},{"type":"text","content":"The CNSide® CSF Assay Platform enables earlier, and more accurate detection and monitoring of leptomeningeal metastases compared to conventional CSF cytology, supporting rapid diagnosis, treatment monitoring, and treatment guidance. The superior clinical utility of CNSide® over standard of ca...